Clinical Trial Update: Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial update on Teclistamab-Daratumumab and Talquetamab-Daratumumab combinations in newly diagnosed high-risk multiple myeloma; the study is currently a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Daratumumab (daratumumab)
• Talquetamab (talquetamab)
• Teclistamab (teclistamab)

Snippet

Sponsor: PETHEMA Foundation | Conditions: High-Risk de Novo Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING